AR059733A1 - Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion - Google Patents
Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacionInfo
- Publication number
- AR059733A1 AR059733A1 ARP070100894A ARP070100894A AR059733A1 AR 059733 A1 AR059733 A1 AR 059733A1 AR P070100894 A ARP070100894 A AR P070100894A AR P070100894 A ARP070100894 A AR P070100894A AR 059733 A1 AR059733 A1 AR 059733A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- heteroaryl
- aryl
- heterocycloalkyl
- cycloalkyl
- Prior art date
Links
- 208000007502 anemia Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 title 2
- 239000002131 composite material Substances 0.000 title 1
- 150000002390 heteroarenes Chemical class 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 9
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 5
- 229910052757 nitrogen Inorganic materials 0.000 abstract 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 4
- 125000005213 alkyl heteroaryl group Chemical group 0.000 abstract 4
- 125000000304 alkynyl group Chemical group 0.000 abstract 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
- 125000002877 alkyl aryl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 108010049175 N-substituted Glycines Proteins 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- -1 bicyclic heteroaromatics Chemical class 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 150000001768 cations Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 229910052717 sulfur Chemical group 0.000 abstract 1
- 239000011593 sulfur Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Compuestos derivados de glicina N-sustituida con heteroaromáticos bicíclicos, de formula (1):en la que: R1 es hidrogeno, -NR3R4, -alquilo C1-10, -alquenilo C2-10, -alquinilo C2-10, -cicloalquilo C3-8, -alquil C1-10-cicloalquilo C3-8, -cicloalquenilo C5-8, -alquil C1-10-cicloalquenilo C5-8, -heterocicloalquilo C3-8, -alquil C1-10-heterocicloalquilo C3-8, -arilo, -alquil C1-10-arilo, -heteroarilo o - alquil C1-10-heteroarilo; R2 es -NR6R7 u -OR8 ; cada uno de R3 y R4 se selecciona independientemente entre el grupo que consiste en hidrogeno, -alquilo C1-10, -cicloalquilo C3-8, -alquil C1-10-cicloalquilo C3-8, -heterocicloalquilo C3-8, -alquil C1-10-heterocicloalquilo C3-8, -arilo, -alquil C1-10-arilo, -heteroarilo, -alquil C1- 10-heteroarilo, -CO(alquilo C1-4), -CO(cicloalquilo C3-8), - CO(heterocicloalquilo C3-6), -CO(arilo), -CO(heteroarilo), -SO2(alquilo C1-4); o R3 y R4 tomados junto con el nitrogeno al que están unidos forman un anillo saturado de 5, 6 o 7 miembros, que contiene opcionalmente otro heteroátomo seleccionado entre oxigeno, nitrogeno y azufre; cada uno de R6 y R7 se selecciona independientemente entre el grupo que consiste en hidrogeno, -alquilo C1-10, -alquenilo C2-10 -alquinilo C2-20, - cicloalquilo C3-8, -heterocicloalquilo C3-8, -arilo y -heteroarilo; R8 es H, un cation o -alquilo C1-10 que está sin sustituir o sustituido con uno o más sustituyentes seleccionados independientemente entre el grupo que consiste en -cicloalquilo C3- 6, -heterocicloalquilo, -arilo y - heteroarilo; W, X, Y y Z son independientemente CR9 o nitrogeno y al menos 1 o 2 de W, X, Y o Z es nitrogeno pero no son todos simultáneamente nitrogeno; cada R9 se selecciona independientemente entre el grupo que consiste en hidrogeno, nitro, ciano, halogeno, -alquilo C1-4 mono-, di- o trihalosustituido, C(O)R5, -C(O)OR5, -OR5, -SR5 -S(O)R5 -S(O)2R5, -NR3R4, -CONR3R4, -N(R3)C(O)R5, -N(R3)C(O)OR5, -N(R3)CH2C(O)OR5, -OC(O)NR4, -N(R3)C(O)NR3R4, -P(O)(OR5)2, - SO2NR3R4, -N(R3)SO2R5 y un grupo -alquilo C1-10, -alquenilo C1-10, -alquinilo C1-10, cicloalquilo C3-6, -heterocicloalquilo C3-6, -arilo y - heteroarilo; cada R5 se selecciona independientemente entre el grupo que consiste en hidrogeno, -alquilo C1- 10, -alquenilo C2-10, -alquinilo C2-10, -CO(alquilo C1-4), -CO(arilo), -CO(heteroarilo), -CO(cicloalquilo C3-6), -CO(heterocicloalquilo C3-6), -SO2(alquilo C1-4), -cicloalquilo C3-8, -heterocicloalquilo C3-8, - arilo C6-14, -alquil C1-10-arilo, - heteroarilo y -alquil C1-10-heteroarilo; donde cualquier carbono o heteroátomo de R1, R2, R3, R4, R5, R6, R7, R8 o R9 está sin sustituir o, cuando sea posible, está sustituido con uno o más sustituyentes seleccionados independientemente entre el grupo que consiste en -alquilo C1-6, -alquilo C1-4 mono-, di- o trihalosustituido; -arilo; -heteroarilo; halogeno; -OR5 -NR3R4, ciano; nitro; -C(O)R5 -C(O)OR5 -SR5, -S(O)R5 -S(O)2R5-NR3R4, -CONR3R4, -N(R3)C(O)R5, -N(R3)C(O)OR5, -OC(O)NR3R4 - N(R3)C(O)NR3R4, -SO2NR3R4, -N(R3)SO2R5, -alquenilo C1-10, -alquinilo C1-10, -cicloalquilo C3-6, -heterocicloalquilo C3-6, -arilo y un grupo -heteroarilo; donde R3, R4y R5 son como se han definido anteriormente; o una sal farmacéuticamente aceptable del mismo. Composicion farmacéutica que lo comprende. Uso para preparar un medicamento para tratar la anemia y proceso para la preparacion de dichos compuestos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77973706P | 2006-03-07 | 2006-03-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR059733A1 true AR059733A1 (es) | 2008-04-23 |
Family
ID=38475787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070100894A AR059733A1 (es) | 2006-03-07 | 2007-03-05 | Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US7897612B2 (es) |
| EP (1) | EP1991227A2 (es) |
| JP (1) | JP2009529536A (es) |
| AR (1) | AR059733A1 (es) |
| PE (1) | PE20071020A1 (es) |
| TW (1) | TW200808793A (es) |
| WO (1) | WO2007103905A2 (es) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2576765C (en) * | 2004-09-03 | 2013-05-28 | Applied Research Systems Ars Holding N.V. | Pyridine methylene azolidinones and use thereof phosphoinositide inhibitors |
| US7588924B2 (en) | 2006-03-07 | 2009-09-15 | Procter & Gamble Company | Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase |
| EP2044005B8 (en) * | 2006-06-26 | 2012-12-05 | Warner Chilcott Company, LLC | Prolyl hydroxylase inhibitors and methods of use |
| US7635715B2 (en) | 2006-12-18 | 2009-12-22 | Amgen Inc. | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof |
| AU2007334321B2 (en) | 2006-12-18 | 2012-03-08 | Amgen Inc. | Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof |
| WO2008130527A1 (en) * | 2007-04-18 | 2008-10-30 | Merck & Co., Inc. | Novel 1,8-naphthyridine compounds |
| ES2446418T3 (es) | 2007-04-18 | 2014-03-07 | Amgen, Inc | Derivados de indanona que inhiben la prolil hidroxilasa |
| WO2008130600A2 (en) * | 2007-04-18 | 2008-10-30 | Amgen Inc. | Quinolones and azaquinolones that inhibit prolyl hydroxylase |
| EP2150251B9 (en) | 2007-05-04 | 2013-02-27 | Amgen, Inc | Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity |
| CA2685219C (en) | 2007-05-04 | 2012-06-19 | Amgen Inc. | Diazaquinolones that inhibit prolyl hydroxylase activity |
| US8962530B2 (en) * | 2007-06-27 | 2015-02-24 | Regents Of The University Of Colorado | Inflammatory bowel disease therapies |
| WO2009039322A1 (en) * | 2007-09-19 | 2009-03-26 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009039323A1 (en) * | 2007-09-19 | 2009-03-26 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009039321A1 (en) * | 2007-09-19 | 2009-03-26 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009049112A1 (en) * | 2007-10-10 | 2009-04-16 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009073497A2 (en) * | 2007-11-30 | 2009-06-11 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| CN101932324A (zh) * | 2007-11-30 | 2010-12-29 | 葛兰素史密斯克莱有限责任公司 | 脯氨酰羟化酶抑制剂 |
| WO2009073669A1 (en) | 2007-12-03 | 2009-06-11 | Fibrogen, Inc. | Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions |
| EP2240178A4 (en) * | 2007-12-19 | 2011-10-26 | Glaxosmithkline Llc | PROLYLHYDROXYLASEHEMMER |
| US8952160B2 (en) | 2008-01-11 | 2015-02-10 | Fibrogen, Inc. | Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity |
| US8324405B2 (en) | 2008-02-05 | 2012-12-04 | Fibrogen, Inc. | Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors |
| EP2257171B1 (en) * | 2008-02-25 | 2016-02-10 | Merck Sharp & Dohme Corp. | Tetrahydro-1h-pyrrolo-fused pyridones |
| US8471024B2 (en) * | 2008-02-25 | 2013-06-25 | Merck Sharp & Dohme, Corp. | Tetrahydrofuropyridones |
| SI2294066T1 (sl) | 2008-04-28 | 2014-12-31 | Janssen Pharmaceutica N.V. | Benzoimidazoli kot inhibitorji prolil-hidroksilaze |
| US20110039895A1 (en) * | 2008-04-30 | 2011-02-17 | Glaxo Smith Kline LLC., a corporation | Prolyl hydroxylase inhibitors |
| GB0809262D0 (en) | 2008-05-21 | 2008-06-25 | Isis Innovation | Assay |
| US8217043B2 (en) | 2008-08-20 | 2012-07-10 | Fibrogen, Inc. | Compounds and methods for their use |
| US20110144167A1 (en) * | 2008-08-25 | 2011-06-16 | Smithkline Beecham Corporation | Prolyl Hydroxylase Inhibitors |
| NZ592741A (en) | 2008-11-14 | 2013-03-28 | Fibrogen Inc | Thiochromene derivatives as hif hydroxylase inhibitors |
| WO2010059552A1 (en) * | 2008-11-18 | 2010-05-27 | Glaxosmithkline Llc | Prolyl hydroxylase inhibitors |
| FR2940652B1 (fr) * | 2008-12-29 | 2011-02-11 | Sanofi Aventis | Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one,leur preparation et leur application en therapeutique |
| CN102333776B (zh) | 2008-12-29 | 2014-05-21 | 赛诺菲 | 2-吡啶-2-基-吡唑-3(2h)-酮的衍生物、其制备和治疗用途 |
| KR20110099786A (ko) | 2008-12-29 | 2011-09-08 | 사노피 | ２-피리딘-２-일-피라졸-３（２ｈ）-온의 유도체, 그의 제조법 및 ｈｉｆ 활성화제로서의 치료 용도 |
| RU2528412C2 (ru) | 2009-02-10 | 2014-09-20 | Янссен Фармацевтика Нв | Хиназолиноны как ингибиторы пролилгидроксилазы |
| WO2011006355A1 (en) * | 2009-07-15 | 2011-01-20 | Beijing Beta Pharma Inc. | Compounds as hypoxia mimetics, and compositions, and uses thereof |
| HRP20140705T1 (hr) * | 2009-07-17 | 2014-09-12 | Japan Tobacco, Inc. | Spoj triazolopiridina i njegovo djelovanje kao inhibitora prolil hidroksilaze i induktora proizvodnje eritropoetina |
| WO2011031745A1 (en) | 2009-09-09 | 2011-03-17 | Achaogen, Inc. | Antibacterial fluoroquinolone analogs |
| ES2424122T3 (es) | 2009-11-06 | 2013-09-27 | Aerpio Therapeutics Inc. | Inhibidores de la prolilhidroxilasa |
| EP2603502B1 (en) | 2010-08-13 | 2014-07-30 | Janssen Pharmaceutica, N.V. | 4-aminoquinazolin-2-yl-1-pyrrazole-4-carboxylic acid compounds as prolyl hydroxylase inhibitors |
| EP2661265B1 (en) | 2010-12-23 | 2017-03-08 | Merck Sharp & Dohme Corp. | Quinolines and aza-quinolines as crth2 receptor modulators |
| RU2589709C2 (ru) | 2010-12-23 | 2016-07-10 | Мерк Шарп Энд Домэ Корп. | Хиноксалины и азахиноксалины в качестве модуляторов рецептора crth2 |
| CN103608346B (zh) | 2011-02-02 | 2016-06-15 | 菲布罗根有限公司 | 作为缺氧诱导因子(hif)羟化酶抑制剂的萘啶衍生物 |
| GB201102659D0 (en) | 2011-02-15 | 2011-03-30 | Isis Innovation | Assay |
| NO2686520T3 (es) | 2011-06-06 | 2018-03-17 | ||
| CA2837560C (en) | 2011-06-06 | 2017-02-14 | Akebia Therapeutics Inc. | Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer |
| GB201113101D0 (en) | 2011-07-28 | 2011-09-14 | Isis Innovation | Assay |
| EP2776023B1 (en) | 2011-10-25 | 2016-03-09 | Janssen Pharmaceutica, N.V. | Meglumine salt formulations of 1-(5,6-dichloro-1h-benzo[d]imidazol-2-yl)-1h-pyrazole-4-carboxylic acid |
| EA028774B1 (ru) | 2012-12-21 | 2017-12-29 | Квонтисел Фармасьютикалс, Инк. | Ингибиторы гистондеметилазы |
| MY175854A (en) * | 2012-12-24 | 2020-07-14 | Cadila Healthcare Ltd | Novel quinolone derivatives |
| HRP20240319T1 (hr) | 2013-06-13 | 2024-05-24 | Akebia Therapeutics, Inc. | Pripravci i postupci za liječenje anemije |
| US20150164991A1 (en) * | 2013-11-01 | 2015-06-18 | Vanderbilt University | Method and Kit for Evaluating and Monitoring a Treatment Program for Anemia |
| SG10202012791TA (en) | 2013-11-15 | 2021-01-28 | Akebia Therapeutics Inc | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof |
| US10385047B2 (en) | 2014-06-25 | 2019-08-20 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| EP3190104B1 (en) * | 2014-09-02 | 2021-10-27 | Sunshine Lake Pharma Co., Ltd. | Quinolinone compound and use thereof |
| WO2016045127A1 (en) * | 2014-09-28 | 2016-03-31 | Merck Sharp & Dohme Corp. | Inhibitors of hif prolyl hydroxylase |
| HK1247201A1 (zh) | 2015-01-23 | 2018-09-21 | 阿克比治疗有限公司 | 2-(5-(3-氟苯基)-3-羟基吡啶甲醯胺)乙酸的固体形式、其组合物及用途 |
| CN106146395B (zh) | 2015-03-27 | 2019-01-01 | 沈阳三生制药有限责任公司 | 3-羟基吡啶化合物、其制备方法及其制药用途 |
| CN106146491B (zh) * | 2015-03-27 | 2017-12-12 | 沈阳三生制药有限责任公司 | 被芳基或杂芳基取代的5‑羟基‑1,7‑萘啶化合物、其制备方法及其制药用途 |
| SI3277270T1 (sl) | 2015-04-01 | 2022-04-29 | Akebia Therapeutics, Inc. | Sestavki in postopki za zdravljenje anemije |
| SG11201802777XA (en) | 2015-10-14 | 2018-05-30 | X Therma Inc | Compositions and methods for reducing ice crystal formation |
| CN108069957B (zh) * | 2016-11-09 | 2022-11-04 | 广东东阳光药业有限公司 | 脯氨酰羟化酶抑制剂及其用途 |
| CN111163775B (zh) | 2017-10-02 | 2023-07-11 | 勃林格殷格翰国际有限公司 | 作为cdk8/cdk19抑制剂的新型[1,6]萘啶化合物和衍生物 |
| CA3097219A1 (en) | 2018-05-09 | 2019-11-14 | Akebia Therapeutics, Inc. | Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid |
| CN110878096A (zh) | 2018-09-05 | 2020-03-13 | 石药集团中奇制药技术（石家庄）有限公司 | 一种1,7-萘啶类衍生物及其制备方法和用途 |
| US11524939B2 (en) | 2019-11-13 | 2022-12-13 | Akebia Therapeutics, Inc. | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid |
| IL297908A (en) | 2020-05-05 | 2023-01-01 | Teon Therapeutics Inc | Cannabinoid receptor type 2 (cb2) modulators and uses thereof |
| TW202409032A (zh) * | 2022-08-05 | 2024-03-01 | 大陸商上海艾力斯醫藥科技股份有限公司 | 一種稠環化合物、其製備方法及其應用 |
| EP4342885A1 (en) | 2022-09-20 | 2024-03-27 | Basf Se | N-(3-(aminomethyl)-phenyl)-5-(4-phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-amine derivatives and similar compounds as pesticides |
| WO2024061665A1 (en) | 2022-09-20 | 2024-03-28 | Basf Se | N-(3-(aminomethyl)-phenyl)-5-(4-phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-amine derivatives and similar compounds as pesticides |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103145616B (zh) * | 2003-06-06 | 2015-09-30 | 菲布罗根有限公司 | 含氮杂芳基化合物及其在增加内源性促红细胞生成素中的用途 |
| EP1720856B1 (en) * | 2004-02-11 | 2013-08-14 | GlaxoSmithKline LLC | Hiv integrase inhibitors |
-
2007
- 2007-03-05 PE PE2007000237A patent/PE20071020A1/es not_active Application Discontinuation
- 2007-03-05 AR ARP070100894A patent/AR059733A1/es not_active Application Discontinuation
- 2007-03-05 TW TW096107424A patent/TW200808793A/zh unknown
- 2007-03-06 WO PCT/US2007/063359 patent/WO2007103905A2/en not_active Ceased
- 2007-03-06 US US12/281,677 patent/US7897612B2/en not_active Expired - Fee Related
- 2007-03-06 US US11/682,362 patent/US20070213335A1/en not_active Abandoned
- 2007-03-06 JP JP2008558499A patent/JP2009529536A/ja active Pending
- 2007-03-06 EP EP07757957A patent/EP1991227A2/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| TW200808793A (en) | 2008-02-16 |
| US20090082357A1 (en) | 2009-03-26 |
| US20070213335A1 (en) | 2007-09-13 |
| PE20071020A1 (es) | 2007-12-11 |
| WO2007103905A2 (en) | 2007-09-13 |
| WO2007103905A3 (en) | 2008-10-30 |
| JP2009529536A (ja) | 2009-08-20 |
| US7897612B2 (en) | 2011-03-01 |
| EP1991227A2 (en) | 2008-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR059733A1 (es) | Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion | |
| AR061570A1 (es) | Compuesto de glicina sustituido en el n heteroaromatico composicion farmaceutica que lo comprende, su uso para preparar un medicamento, procedimientos para preparar dicha composicion farmaceutica y para preparar el compuesto | |
| UY39786A (es) | Derivados de Triazolopirimidina y su uso en el Tratamiento de Enfermedades | |
| ECSP20021913A (es) | Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso | |
| EA201591050A1 (ru) | Имидазопиридиновые соединения | |
| AR081830A1 (es) | Activadores de guanilato ciclasa soluble, composiciones farmaceuticas que los comprenden y sus usos | |
| BR112018008880A8 (pt) | composto 7-(tiazol-5-il) pirrolopirimidina como agonista de tlr7 | |
| AR080725A1 (es) | Analogos para el tratamiento o prevencion de infecciones por flavivirus y composiciones farmaceuticas que las comprenden | |
| AR044513A1 (es) | Inhibidores de serina proteasas, particularmente de la proteasa ns3-ns4a del hcv | |
| MY169766A (en) | 1-heterocyclyl-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one derivatives and their use as pde9a modulators | |
| DOP2013000191A (es) | Derivados de heteroarilo como modulares de nachr alfa 7 | |
| AR064608A1 (es) | Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer. | |
| AR034137A1 (es) | Un compuesto de biciclo-pirazol, su uso, un procedimiento para su preparacion, una composicion farmaceutica que lo comprende, y una biblioteca quimica combinatoria | |
| AR057423A1 (es) | 2,4-diamino-pirimidinas como inhibidores de aurora, preparacion farmaceutica y uso del compuesto para preparar un medicamento | |
| DOP2012000144A (es) | Procedimiento para la preparacion de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilcarbamato de metilo y su purificacion para su uso como principio activo farmaceutico | |
| DOP2013000276A (es) | Nuevos derivados de imidazol útiles para el tratamiento de artritis | |
| AR032128A1 (es) | Compuestos moduladores del receptor glucocorticoide, uso de los mismos en fabricacion de medicamentos, composiciones, y conjuntos intermediarios y proceso de preparacion | |
| BR112014002397A2 (pt) | composição farmacêutica contendo derivado de diamina | |
| AR063266A1 (es) | Derivados de 3- amino- imidazo [1,2-a] piridina | |
| UY33485A (es) | Derivados de acido(2-ariloxiacetilamino)fenilpropionico, procedimientos para su preparacion y uso de los mismos como medicamentos. | |
| CL2013002740A1 (es) | Compuestos macrociclicos analogos de sangliferina, inhibidores de la ciclofilina; procedimiento de preparacion; intermediario; composicion farmaceutica; y uso en el tratamiento de infecciones virales tales como infeccion por vhc o vih, o uso como inmunosupresor o agente antiinflamatorio. | |
| AR067927A1 (es) | Quinolinas sustituidas, composiciones y combinaciones que las comprenden y el uso de las mismas en la preparacion de un medicamento para tratamiento de enfermedades inflamatorias y/o alergicas del tracto respiratorio. | |
| AR037100A1 (es) | Compuesto de pirimidina de anillo fusionado alquinilado, proceso de preparacion, compuestos intermedios, composicion farmaceutica y usi para preparacion de un producto medicinal | |
| UY35338A (es) | Compuestos bicíclicos moduladores de la actividad de s1p1 y composiciones farmacéuticas que los contienen | |
| DOP2015000132A (es) | Moduladores selectivos del receptor de andrógenos novedosos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |